REGENXBIO (RGNX) News Today $7.37 +0.22 (+3.08%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121January 16 at 9:37 PM | seekingalpha.comRegenXBio: Strategic Partnerships and Promising Pipeline Drive Buy RatingJanuary 16 at 7:32 AM | markets.businessinsider.comRegenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)January 15, 2025 | benzinga.comHC Wainwright Reiterates "Buy" Rating for REGENXBIO (NASDAQ:RGNX)HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday.January 15, 2025 | marketbeat.comBank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)January 15, 2025 | markets.businessinsider.comRegenxbio stock surges on strategic partnership deal with Nippon ShinyakuJanuary 14, 2025 | investing.comREGENXBIO partners with Nippon Shinyaku for MPS therapiesJanuary 14, 2025 | msn.comRegenxbio, Nippon Shinyaku enter commercialization pact for RGX-121January 14, 2025 | markets.businessinsider.comRockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon ShinyakuJanuary 14, 2025 | bizjournals.comStrategic Partnerships and Promising Pipeline Drive Buy Rating for RegenXBioJanuary 14, 2025 | markets.businessinsider.comRegenXBio Partners with Nippon Shinyaku on Gene TherapiesJanuary 14, 2025 | tipranks.comREGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS DiseasesJanuary 14, 2025 | prnewswire.comAbbVie, Regenxbio provide updates on ABBV-RGX-314 clinical programJanuary 13, 2025 | markets.businessinsider.comAbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical ProgramJanuary 13, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Receives $35.27 Consensus Target Price from AnalystsJanuary 9, 2025 | americanbankingnews.comJPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)JPMorgan Chase & Co. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 17.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,477,311 shares of the biotechnology company's stock after selling 535,165 sharJanuary 8, 2025 | marketbeat.comRegenxbio price target lowered to $22 from $25 at BofAJanuary 7, 2025 | markets.businessinsider.comRegenxbio price target lowered to $30 from $35 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The avJanuary 6, 2025 | marketbeat.comBarclays PLC Purchases 67,948 Shares of REGENXBIO Inc. (NASDAQ:RGNX)Barclays PLC increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 141.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,024 shares of the biotechnology compaDecember 30, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in DecemberREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 6.1 days.December 30, 2024 | marketbeat.comState Street Corp Has $29.19 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)State Street Corp decreased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,782,883 shares of the biotechnology company's stock after sellingDecember 22, 2024 | marketbeat.comNational Bank of Canada FI Purchases Shares of 68,000 REGENXBIO Inc. (NASDAQ:RGNX)National Bank of Canada FI bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 68,000 shares of the biotechnoloDecember 15, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by AnalystsREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recoDecember 12, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)December 11, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Lowers Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Jacobs Levy Equity Management Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 41.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,218 shares of the biotechnology company's stock afDecember 9, 2024 | marketbeat.comRedmile Group LLC Has $51.33 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Redmile Group LLC grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,892,902 shares of the biotechnology company's stock aftDecember 5, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Makes New $643,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)Connor Clark & Lunn Investment Management Ltd. acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 61,288 shares of the biotechnology company's stock, valued at approximately $6November 29, 2024 | marketbeat.com3 Best Stocks to Buy Now, 11/21/2024, According to Top AnalystsNovember 21, 2024 | msn.comBuy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval ProspectsNovember 21, 2024 | markets.businessinsider.comRegenxbio price target lowered to $36 from $40 at H.C. WainwrightNovember 21, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock PriceHC Wainwright cut their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a research report on Thursday.November 21, 2024 | marketbeat.comLeerink Partnrs Increases Earnings Estimates for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology companyNovember 21, 2024 | marketbeat.comChardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX)Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday.November 20, 2024 | marketbeat.comRegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA PlansNovember 19, 2024 | markets.businessinsider.comPromising Initial Data and Favorable Regulatory Pathway Support Buy Rating for RegenXBio’s RGX-202 in DMD TreatmentNovember 19, 2024 | markets.businessinsider.comWhat's Going On With REGENXBIO Shares Monday?November 18, 2024 | benzinga.comRegenxbio initiates pivotal phase of Affinity Duchenne trial of RGX-202November 18, 2024 | markets.businessinsider.comPromising Developments in RegenXBio’s RGX-202 Program Drive Buy RatingNovember 18, 2024 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading Volume - Time to Buy?REGENXBIO (NASDAQ:RGNX) Sees Strong Trading Volume - Time to Buy?November 18, 2024 | marketbeat.comREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATANovember 18, 2024 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendNovember 17, 2024 | marketbeat.comOptimistic Growth Potential for RegenXBio Amidst Delivery Challenges and Promising Gene Therapy AdvancesNovember 16, 2024 | markets.businessinsider.comRegenxbio assumed with an Overweight at Morgan StanleyNovember 16, 2024 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Shares Gap Up - What's Next?REGENXBIO (NASDAQ:RGNX) Shares Gap Up - Still a Buy?November 15, 2024 | marketbeat.comREGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan StanleyMorgan Stanley reaffirmed an "overweight" rating and issued a $22.00 price target on shares of REGENXBIO in a report on Friday.November 15, 2024 | marketbeat.comREGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202November 14, 2024 | prnewswire.comHC Wainwright Increases Earnings Estimates for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of REGENXBIO in a report released on Thursday, November 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($4.92)November 11, 2024 | marketbeat.comREGENXBIO FY2024 EPS Estimate Reduced by Leerink PartnrsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2024 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology companyNovember 11, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter ReportNovember 9, 2024 | finance.yahoo.com Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼0.150.41▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼155▲RGNX Articles Average Week Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News KNSA News RCUS News OCUL News MRVI News ARVN News CALT News DAWN News PRAX News ANIP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGNX Stock Alerts